Navigation Links
New Positive Pre-clinical Data for Active Biotech's RA Project I-3D

LUND, June 15, 2007-Active Biotech (OMX Nordic: ACTI) presented pre-clinical results for the project I-3D at the annual EULAR (The European League Against Rheumatism, www.eular.org ) conference, June 13-16*.

"The new pre-clinical data presented show that I-3D has a significant inhibitory effect on disease development in an experimental model for rheumatoid arthritis (RA)", commented Sven Andréasson, President & CEO Active Biotech.

An additive inhibitory effect on disease development is achieved when I-3D is combined with methotrexate, an anti-proliferative drug widely used for the treatment of various inflammatory disorders and cancer.

The results strengthen further clinical development of I-3D as monotherapy or in combination with methotrexate.

Lund, June 15, 2007

Active Biotech AB (publ)

Sven Andréasson President and CEO

About I-3D The I-3D compound is a novel small molecule inhibitor of human dihydroorotate dehydrogenase (DHODH). Inflammatory diseases such as RA involve rapidly proliferating T cells with an exceptional requirement for de novo pyrimidine biosynthesis. DHODH inhibition results in inhibition of de novo pyrimidine synthesis and thereby inhibition of T-cell proliferation.

In May 2006, Active Biotech and Chelsea Therapeutics International Ltd (NASDAQ:CHTP) signed an agreement for the co-development and commercialization of I-3D. Under the agreement, Active Biotech and Chelsea will jointly conduct and fund the clinical development of the I-3D portfolio.

A candidate drug is planned to be selected this year for further clinical trials in 2008.

*For further information and to view the complete poster "ABR-224050: a novel dihydroorotate dehydrogenase inhibitor suppressing disease development in collagen induced arthritis", please visit www.activebiotech.com.

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is conducted in cooperation with Chelsea Therapeutics International Ltd.

Active Biotech AB P.O. Box 724, SE-220 07 Lund, Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 20 50


'"/>




Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
(Date:5/3/2017)... 2017  West Pharmaceutical Services, Inc. (NYSE: WST), ... drug administration, announced today that Fran DeGrazio ... and Diane Paskiet , Director, Scientific Affairs, ... on West,s expertise in the areas of safety ... providing commentary on updated industry guidance. ...
(Date:5/2/2017)... SYDNEY , May 2, 2017  George Clinical, ... Asia-Pacific region, and Vector Oncology, a ... research and data analytics, formally announced today that George ... immediately, the transaction has the dual purpose of ... scientifically led oncology trial delivery solutions throughout the ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... In ... choosing the most appropriate instruments for research and understanding the basic principles that ... webinar will focus on innovations in stereo microscopy for brightfield and fluorescence typically ...
(Date:5/24/2017)... ... May 24, 2017 , ... Altec Products, Inc., a ... 2017 – a one-day technology conference in San Diego, CA. , At nVerge ... users to fully utilize and enhance their Sage ERP solutions by providing improved visibility ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... implants in Bayside, NY, who have now spent 10 years as clinical instructors ... York University (NYU) College of Dentistry. Through the program, private practitioners receive cutting-edge ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Patients who want ... OH, can now meet with Dr. Joseph Bedich for a consultation, with or without ... improving their oral health and functionality. , Dr. Bedich offers a variety ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Myers Jackson ... his has the ability to sell luxury homes anywhere on the planet. The luxury ... county side from Hattiesburg to Houston city-scapes. A quick search of “11 Spyglass Hill ...
Breaking Medicine News(10 mins):